Summary of opinion: Metacam, 17/01/2024 Positive

On 16 – 17 January 2024, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a group of variations to the terms of the marketing authorisation for the veterinary medicinal product Metacam.

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/veterinary/variation/metacamhttps://www.ema.europa.eu/en/medicines/veterinary/variation/metacam
Retrieved on: 
星期五, 一月 19, 2024
Information
Tags: 
European Medicines Agency, NSAID, Meloxicam, Civil service commission, European Commission, Dog, Intention, CVMP, UPD, Cat, SPC, Marketing, Committee
Geotags: 
GUINEA, EUROPEAN UNION
摘要
Key Points: 
  • On 16 – 17 January 2024, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a group of variations to the terms of the marketing authorisation for the veterinary medicinal product Metacam.
  • The marketing authorisation holder for this veterinary medicinal product is Boehringer Ingelheim Vetmedica GmbH.
  • Metacam is currently authorised for various therapeutic indications in different target species and is available as several pharmaceutical forms and strengths.
  • The active substance is meloxicam, a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class.
Copyright: 
2024 European Medicines Agency. All Rights Reserved.